drugset / Trial / NCT05083754
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Phase 1
Recruiting
50 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Incyte Corporation · collab
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.
Timeline
- Start
- 2022-08-31
- Primary completion
- 2028-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retifanlimab | Monoclonal antibody | — | — |
| Subject | Temozolomide | Small molecule | — | — |